Dr. Vokes on Recent Progress in the Treatment Landscape of Head and Neck Cancer
January 19th 2017Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses recent progress in the treatment landscape of head and neck cancer.
Dr. Vokes on Moving Immunotherapy into Frontline for Head and Neck Cancer
January 6th 2017Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses the possibility of moving immunotherapy agents into the frontline setting for patients with head and neck cancer.
Dr. Vokes on Selecting Nivolumab or Pembrolizumab for Head and Neck Cancer Treatment
December 28th 2016Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses how to choose between nivolumab (Opdivo) and pembrolizumab (Keytruda) for second-line treatment for patients with head and neck cancer.
Dr. Seiwert on Prognosis for Patients With Head and Neck Cancer
December 23rd 2016Tanguy Y. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the current prognosis for patients with head and neck cancer prior to the FDA approvals of immunotherapy agents nivolumab (Opdivo) and pembrolizumab (Keytruda) as treatments.
Dr. Vokes on Curative Treatment Approaches in Head and Neck Cancer
December 2nd 2016Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses curative treatment approaches for patients with head and neck cancer.
IDO Inhibitors Among Immunotherapy Strategies Under Study in Glioblastoma
November 30th 2016The concept of using immunotherapies to treat patients with glioblastoma multiforme is gaining ground among researchers who are interested not only in evaluating checkpoint blockade agents that have proved effective in other tumor types but also in exploring novel targets.
Dr. Zagaja on Major Benefit With Prostatectomy
November 1st 2016Gregory Zagaja, MD, professor of Surgery, director of the Prostate Cancer Center at the University of Chicago Medicine, discusses the benefits of radical prostatectomy for patients with prostate cancer. Zagaja shared this insight during an interview at the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Dr. Eggener on PSA-Based Screening in Early-Stage Prostate Cancer
October 31st 2016Scott Eggener, MD, associate professor of Surgery, Urologic Oncology, at the University of Chicago Medicine, discusses his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer. Eggier shared these thoughts during the 2016 OncLive State of the Science Summit on GU and Prostate Cancer.
Combo Trials Aim to Clarify Optimal Radium-223 Use in mCRPC
August 16th 2016Russell Szmulewitz, MD, discusses the unknown optimal use of radium-223 dichloride (Xofigo), the appropriate time to administer it, and the associated challenges with the agent for the treatment of patients with metastatic castration-resistant prostate cancer.
Dr. Patnaik on Challenges With Sequencing Therapies in mCRPC
August 11th 2016Akash Patnaik, MD, PhD, assistant professor of Medicine at the University of Chicago Medicine, discusses the challenges with sequencing available agents for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Expert Explores Next Steps With "Game Changer" Atezolizumab in Bladder Cancer
August 11th 2016Gary D. Steinberg, MD, discusses the impact of atezolizumab (Tecentriq) on the treatment landscape of bladder cancer, the resistance to finding effective therapies for the disease, and what potential role immunotherapy may have in the field going forward.
Expert Stresses Importance of PSA-Based Screening in Early-Stage Prostate Cancer
July 21st 2016Scott Eggener, MD, discusses the implications of the Prostate, Lung, Colorectal, and Ovary trial update, and shares his views on PSA-based screening and how to appropriately use it for patients with early-stage prostate cancer.